BioLargo reports record 2024 revenues of $17.8M, up 45% YoY; net loss narrows 6%

BIOLARGO, INC.

Revenue $17.779M, up 45% from 2023; tenth consecutive year of revenue growth.
Net loss $4.347M, down 6% YoY; $3.490M of loss from Clyra Medical operations.
Issued 42% fewer shares in 2024 vs 2023; cash and equivalents $3.548M at Dec 31.
Clyra surgical irrigation products progressing toward national rollout with distribution partner.
Non-cash expenses (stock/options) $2.479M, representing 57% of net loss.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.